Related Experiment Video
Updated: Oct 14, 2025

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
Published on: December 15, 2014
Power washing pulmonary alveolar proteinosis
Tiana R Endicott-Yazdani1, Gary S Schwartz2, Haiying Zhang3
1Department of Pulmonary and Critical Care Medicine, Baylor University Medical Center, Dallas, Texas.
Pulmonary alveolar proteinosis (PAP) treatment can be challenging due to severe hypoxemia. Whole-lung lavage using veno-venous extracorporeal membrane oxygenation (VV ECMO) offers a life-saving option for severe PAP cases.
Area of Science:
- Pulmonology
- Critical Care Medicine
Background:
- Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by surfactant accumulation in alveoli, leading to progressive dyspnea and hypoxemia.
- Severe PAP can be fatal if left untreated, with standard treatment being whole-lung lavage (WLL).
Observation:
- Patients with severe PAP often experience profound hypoxemia, precluding tolerance of single-lung ventilation required for conventional WLL.
- Previous case reports suggest the utility of VV ECMO for WLL in isolated instances.
Findings:
- This study successfully treated three patients with severe PAP using WLL supported by VV ECMO.
- VV ECMO provided essential oxygenation support, enabling the performance of WLL in critically ill patients.
Implications:
- VV ECMO-supported WLL represents a viable and potentially life-saving therapeutic strategy for severe pulmonary alveolar proteinosis.
- This approach may expand treatment options for patients with severe respiratory compromise due to PAP, improving outcomes.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Chest Physiotherapy
Purpose
CPT is primarily used for patients with excessive bronchial secretions who have difficulty clearing...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

